Grace Therapeutics, Inc. — Investor Relations & Filings

Grace Therapeutics, Inc. is a late-stage biopharmaceutical company that develops drug candidates for rare and orphan diseases, with a primary focus on neurological conditions. The company's lead clinical asset is GTx-104, a novel intravenous (IV) formulation of nimodipine for the treatment of aneurysmal subarachnoid hemorrhage (aSAH), a life-threatening brain injury. GTx-104 is designed to overcome the clinical challenges of the current oral standard of care, such as administration difficulties in critically ill patients and high pharmacokinetic variability. The product is currently in a pivotal Phase 3 clinical trial. Grace Therapeutics utilizes proprietary drug delivery technologies to improve the performance of marketed drugs, and its lead assets have received Orphan Drug Designation from the U.S. Food and Drug Administration.